7xm asia login register

7xm asia login register NKMax currently holds master global rights to the intellectual property ("IP”) for troculeucel (formerly known as SNK01) and other proprietary IP that is licensed to NKGen for markets outside Asia. Such an acquisition is expected to put global rights under the control of NKGen. Prior to entering into the rehabilitation process, NKMax announced plans and commenced initial groundwork to commercialize the troculeucel treatment for Alzheimer's and other neurodegenerative diseases in Japan and South Korea, where such NK cell treatment is legal already. Additional production capacity at NKMax's GMP facility will be an added benefit which could help accelerate production for US trials. " As we have made tremendous progress in our clinical program especially with the launch of our phase II trial for moderate stage Alzheimer's disease, we felt that it was essential for us to preserve the very close scientific and clinical partnership with the NKMax team, rather than have NKMax acquired by someone without any cell therapy knowledge or experience”, commented Paul Y. Song, MD, Chairman and CEO of NKGen Biotech. "As we continue to work towards US FDA approval, we will be able to begin to commercialize troculeucel in countries like Japan, Thailand, Malaysia, Mexico and others where an autologous non-genetically modified cell therapy is considered as a legal treatment and already readily available. We believe that we will be much stronger and will deliver more value for our patients and shareholders when operated as one global team.” NKGen does not believe the NKMax rehabilitation process has had any material negative impact on NKGen's business or prospects. About Troculeucel Troculeucel is a novel cell-based, patient specific ex vivo expanded autologous natural killer ("NK”) cell, immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ("INN”) for SNK01 assigned by the World Health Organization ("WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on our journey toward bringing this therapy to market. About NKMax Founded in 2002 and headquartered in Seoul, South Korea, NKMax Co., Ltd. is a clinical-stage biotechnology company focused on advancing immune cell therapies. In addition to its therapeutic innovations, NKMax develops and commercializes bioreagents and immunodiagnostic kits, with revenues derived from these products as well as health supplements. In 2016, NKMax completed its GMP-certified manufacturing facility, and obtained approval from the Korean MFDS (Ministry of Food and Drug Safety) in 2018, strengthening its capabilities in high-quality cell therapy production. Listed on the KOSDAQ, a South Korean stock exchange, NKMax's trading has since been suspended during the course of ongoing rehabilitation efforts. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com . Forward-Looking Statements Statements contained in this press release may contain "forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate”, "believe”, "could”, "continue”, "expect”, "estimate”, "may”, "plan”, "outlook”, "future” and "project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the closing of the Acquisition, which may not close on the terms or timing anticipated, or at all, the satisfaction or waiver of any conditions to the closing of the Acquisition, the anticipated impacts or benefits of the Acquisition, the closing of the expected funding for the Acquisition, the risk of shareholder litigation in connection with the Acquisition, including resulting expense or delay; the risk that NKMax's business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected, the successful and timely completion and the commercialization of troculeucel, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors” and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at www.sec.gov and on the Company's website under the subheading "Investors-Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP) SVP, Corporate Affairs 949-396-6830 [email protected] External Contacts: Chris Calabrese Managing Director LifeSci Advisors, LLC [email protected] Kevin Gardner Managing Director LifeSci Advisors, LLC [email protected]F1 expands grid, adds Cadillac brand and new American team for '26

Kris Zacuto presents Introducing an unparalleled experience at Woodson in Playa Vista. Exuding effortless luxury, this home has been completely reimagined with every surface enhanced and no expense spared. The custom design and renovation creates a one of one Nobu inspired vibe using high end materials and subtle finishes that bring the custom elegance to life. The kitchen design was a focal point of the passion project, creating a showstopping unique design unlike anything else in Playa Vista. A tree lined courtyard enhances the privacy of the home, and brings a cross breeze through the patio to the living room. Beyond turn key, this home is completed by high end finishes,furnishings, and design as well state of the art equipment and technology throughout the home. Address: 5837 Lantern Ct, Playa Vista, CA 90094 Price : $3,099,000 Photo credit: Neufocus For more information, please contact Kris Zacuto at 310.702.6299 or kris@kriszacuto.com . Kris Zacuto is one of the exclusive agents representing the Silicon Beach, CA, real estate market as a member of the Haute Residence Real Estate Network. View all of his listings here.

Hasbro Inc. stock rises Friday, outperforms marketChiefs keep winning despite an O-line problem that has wreaked havoc with their offense KANSAS CITY, Mo. (AP) — It took until the fourth quarter, when Kansas City was desperately trying to fend off the lowly Las Vegas Raiders, for Chiefs coach Andy Reid to finally make a drastic change to his offensive line. Dave Skretta, The Associated Press Nov 30, 2024 10:00 AM Nov 30, 2024 10:05 AM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Las Vegas Raiders defensive end Maxx Crosby (98) attempts to sack Kansas City Chiefs quarterback Patrick Mahomes (15) during the second half of an NFL football game in Kansas City, Mo., Friday, Nov. 29, 2024. (AP Photo/Ed Zurga) KANSAS CITY, Mo. (AP) — It took until the fourth quarter, when Kansas City was desperately trying to fend off the lowly Las Vegas Raiders, for Chiefs coach Andy Reid to finally make a drastic change to his offensive line. The Chiefs had tried Kingsley Suamataia at left tackle to start the season. When the rookie was getting beaten routinely for pressure and sacks, they switched to second-year pro Wanya Morris, who fared no better at protecting Patrick Mahomes . In the waning minutes of a 19-17 victory Friday — one that wasn't secure until Las Vegas fumbled away a chance at a winning field goal with 15 seconds left — the Chiefs slid All-Pro left guard Joe Thuney out to tackle. Mike Caliendo entered at guard. And while they didn't have much chance to work together, the move underscored what's been a season-long problem. “That was the right thing to do at the time,” Reid said afterward. “It just solidified things.” What is the solution moving forward? Well, the Chiefs signed former Pro Bowl left tackle D.J. Humphries last week, but he's been with the team for only a few days, and he's also coming off an ACL tear that sidelined him for the entire offseason. In a perfect world, Humphries would slide into the lineup in time for the Chiefs' game against the Chargers next Sunday. In a more realistic world, the Chiefs may need to make it through another week or two before he's ready to contribute, and that would mean putting Morris back into the lineup or keeping Thuney protecting Mahomes' blind side. “I would tell you it's disruptive to any offense when the quarterback is hit," Reid acknowledged, “and not able to get the ball off." Mahomes had gone 113 straight starts without being sacked five-plus times in a game; Carolina and Las Vegas have done it in consecutive weeks. And along with the sacks have been penalties on Morris and right tackle Jawaan Taylor, which have made it hard for a Kansas City offense that has had to adapt to injuries all season to consistently put together drives. “We have to make sure we clean those things up,” Reid said. “It's hard to go backwards in this league and win games.” Yet the Chiefs keep doing it. They have won an NFL-record 14 straight one-possession games, including five decided on the final play, this season. That has allowed them to piece together an 11-1 record and already clinch a postseason bye. “You're not satisfied with where we're at, even though we're winning football games,” Mahomes said. “Our goal over these last few games is to prove the team we really are going into the playoffs and play that way in the playoffs.” What’s working The passing game has started to produce — when Mahomes has time to throw — now that DeAndre Hopkins has become more ingrained in the offense. He had four catches for 90 yards against the Raiders, and his mere presence has opened things up for others, including Travis Kelce, who had seven catches for 68 yards. What needs help The Chiefs basically abandoned an unproductive running game against Las Vegas. Isiah Pacheco ran seven times for 44 yards in his return from an ankle injury, but 34 yards came on one carry. Kareem Hunt had 15 yards on his seven attempts. Stock up Two-time All-Pro defensive tackle Chris Jones had been held without a sack for seven consecutive games, but he managed to bring down Raiders quarterback Aidan O'Connell twice. That was important given how much trouble the Chiefs have had getting to the quarterback when they aren't blitzing this season. Stock down The entire Kansas City secondary has struggled for weeks, ever since cornerback Jaylen Watson was lost to a season-ending ankle injury. Nazeeh Johnson, Chamarri Conner and Bryan Cook in particular have been inconsistent in their coverage. Injuries The Chiefs made it through the Raiders game without any injuries. Key number 10 — The Chiefs have qualified for the playoffs for 10 consecutive seasons. That is the second-longest streak in NFL history behind the Patriots, who made it 11 straight years from 2009-19. Next steps The game against the Raiders on Black Friday means the Chiefs have a couple of extra days to prepare for the Chargers. The Chiefs have beaten them six straight times, including a 17-10 win on Sept. 29 in Los Angeles. ___ AP NFL: https://apnews.com/hub/nfl Dave Skretta, The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Football (NFL) Bucs QB Baker Mayfield looks to remain unbeaten against the Panthers, who cut him in 2022 Nov 30, 2024 9:30 AM Chiefs recover botched snap by Raiders in closing seconds, clinch playoff berth with 19-17 victory Nov 29, 2024 6:49 PM Colts begin final 5-game stretch against Patriots with a chance to make a run at the playoffs Nov 29, 2024 6:11 PM

India has an answer to Canada’s SDS visa cancellation: What students need to knowThe Eagle Valley girls volleyball team had four players named to the Western Slope all-league team for the 2024 season. Aspen Misch and Taylor Hooper earned first-team recognition and Zakia Shreeve and Riley Weatherred were named to the second team. Misch was also invited to play in the Colorado Coaches of Girls Sports All-State game on Nov. 24. The Devils placed second in the league with an 8-4 record, finishing behind only Battle Mountain (12-0) in the Western Slope standings. They were ousted in the regional tournament on Nov. 11 after falling to Palmer Ridge 3-1 and Green Mountain 3-0. The Huskies later faced Palmer Ridge in the state tournament, but were swept by the defending state champions. “We challenged ourselves to be our best at regionals and I believe we did that,” head coach Mike Garvey stated. “We came out ready to play and stole the first set 25-14. “We competed all night, but just were not the better team.” Coming off an undefeated league record in 2022 and a 2023 season which saw a senior-heavy squad take the Devils to their first state tournament since 2016 , Garvey said before this year began that his current team would need to believe in themselves and embrace the opportunities at hand. In addition to the competitiveness displayed at regionals, the coach said he witnessed growth throughout the season. “We learned many things,” he stated. “The team always responded well when we made mistakes and had to go to the next level in both practice and matches.” Misch had the most blocks on the team (66) and finished tops in hitting percentage (0.264). Hooper — who also was an all-league honorable mention athlete as a sophomore in 2022 — was second in kills (151). Shreeve led the team in kills (163) and aces (61) while Weatherred was tops in assists (289) and second in digs (184) and aces (37). The Devils graduate seven seniors — including all of the above mentioned players except Weatherred, who will be a junior next year — but Garvey is optimistically looking ahead to next fall. “We return four players and our rising senior class is a positive and energetic group,” he said.None